Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Myeloproliferative Disorders 2Myelodysplastic Syndromes 2beta-Thalassemia 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 483pembrolizumab 456Magnetic Resonance Spectroscopy 420Carboplatin 327Cyclophosphamide 315Biopsy 274Cisplatin 270Radiotherapy 244Paclitaxel 229Gemcitabine 225Bevacizumab 214Nivolumab 189fludarabine 184venetoclax 174Drug Therapy 171Dexamethasone 158Blood Specimen Collection 158Oxaliplatin 154Injections 152Capecitabine 152Fluorouracil 145Docetaxel 144Radiosurgery 137Standard of Care 136Rituximab 125Pemetrexed 117durvalumab 114atezolizumab 110Leucovorin 110Radiation 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × luspatercept × 1 year × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡